Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, Immutep Announces Results For First-Line Treatment Of Head And Neck Squamous Cell Carcinoma Patients With Negative PD-L1 Expression

Author: Benzinga Newsdesk | July 12, 2024 03:34am

Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1
High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment
Durability of responses tracks well and over 50% of patients received treatment for at least six months
Combination continues to have a favourable safety profile with no new safety signals observed
Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies

Posted In: IMMP